Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product (Oligonucleotides, Reagents, Services, Equipment/Synthesizer), By Application (PCR Primers, Sequencing, DNA Microarrays), By End-use, By Region, And Segment Forecasts, 2025 - 2030

Oligonucleotide Synthesis Market Summary

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to drive market growth. Demand for molecular diagnostics in precision care is an emerging application field in the oligonucleotide synthesis industry. The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified genetic screening and genome modification. Such innovations influence the demand for oligonucleotide synthesis. Manufacturers invest in technology to enable the production of long oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos. The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly.

Thermo Fisher Scientific Inc. offers oligonucleotides, the starting point for various cutting-edge applications in biology research, drug discovery, and diagnostics. Furthermore, they are ideal for various applications, including PCR, cloning, sequencing, and gene detection. In addition, companies are striving to achieve significant breakthroughs in the oligonucleotide synthesis industry to drive further advancements. In March 2023, Ansa Biotechnologies achieved a substantial breakthrough by successfully synthesizing the longest DNA oligonucleotide to date using a de novo approach.

Market Concentration & Characteristics

The market growth stage is high, and the market growth is accelerating. The oligonucleotide synthesis industry is characterized by a moderate to high degree of innovation due to rapid advancements in gene editing technology. Gene editing technology - Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is projected to be the most influential and innovative technology in biotechnology.

The oligonucleotide synthesis sector is further characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to gain access to new DNA & RNA facilities, increase their capabilities, expand product portfolios, and improve competencies.

The market is also subject to high regulatory scrutiny. Clinical applications of genomics face stringent monitoring and restriction in most countries, while some allow genetic research in sectors other than human use. Changes in regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to significantly influence demand for oligonucleotide synthesis.

The market has a moderate level of product/service expansion. This expansion involves introducing new types of oligonucleotides, improving synthesis technologies, and providing additional services to support customers. Service expansion consists of offering comprehensive solutions, including synthesis, purification, and analytical services.

Regional expansion is a key factor with moderate to high growth in the market. Since several end-user industries are driving demand for oligonucleotide synthesis, the market players are investing in regional expansion to increase production capacity. Furthermore, regional expansion enables players to capture the untapped customer base, thereby contributing to the market's growth.

Product Insights

The services segment dominated the oligonucleotide synthesis market, accounting for the largest revenue share of 31.5% in 2024. This share can be attributed to the growing use of molecular diagnostic tests and the higher adoption of oligonucleotide therapeutics. Moreover, key players are also broadening their offerings by entering new markets or acquiring service providers in different countries. In November 2023, Twist Bioscience, a company focused on genomics and synthetic biology, introduced Express Genes, a new gene synthesis service offering a rapid turnaround time of just 5 to 7 business days. The service, carried out at Twist Bioscience’s manufacturing site in Wilsonville, Oregon, allows for the rapid synthesis of genes.

The oligonucleotides segment is expected to grow at a significant CAGR of 13.0% over the forecast period. This segment's significant growth can be attributed to the rising prevalence of genomic studies, including gene expression analysis and genetic testing. In addition, introducing biochips (DNA chips) for parallel analysis of many clinical samples is anticipated to contribute considerably to the market’s revenue.

The segment is anticipated to witness lucrative growth with the increasing usage of antisense oligonucleotides in clinical trials for conditions such as cardiac disorders, cancer, and ocular dysfunctions. Moreover, the growing awareness and understanding of genetic disorders contribute to the demand for oligonucleotides in diagnostics & potential therapeutic interventions.

Application Insights

PCR primers led the oligonucleotide synthesis industry with the largest revenue share in 2024. Primers are the most widely used oligonucleotides in PCR. They are part of sequences complementary to the 5’ end of the targeted sequence and are used for sequencing or amplification applications. There is a growing adoption of primers for gene sequencing experiments. Their use in fluorescent detection and target amplification has led to various primer designs with different probe- and primer-based detection chemistries. PCR has evolved with technological advancements, resulting in qPCR, RT-PCR, and digital PCR. PCR assays and panels are designed to detect and measure gene expression. The need for primers that suit the application of these enhanced systems for uses such as accurate quantification of gene expression is anticipated to fuel market growth.

The sequencing segment is expected to grow at the fastest CAGR over the forecast period. Sequencing techniques are employed to explore different facets of genomics and genetics. These applications involve the analysis of genetic material, such as DNA and RNA, to better understand the genetic makeup & function of organisms. Sequencing is crucial in identifying and tracking pathogens, particularly for antibiotic-resistant bacteria and emerging viruses. It necessitates rapid and accurate pathogen detection through oligonucleotide-based assays. Advancements in sequencing technologies and bioinformatics tools have also contributed to the growth of this market. In January 2025, DNA Script unveiled advancements in oligonucleotide synthesis technology. The advancement enabled the production of custom DNA sequences of up to 500 nucleotides in length with unmatched complexity.

End-use Insights

The academic research institutes dominated the oligonucleotide synthesis market with the largest revenue share in 2024. Oligonucleotide synthesis is crucial in academic research, forming the backbone of many molecular biology and genomics applications, including PCR, gene editing, site-directed mutagenesis, and diagnostics. The technique offers academic research institutes a rapid, cost-effective method for obtaining custom-made oligonucleotides, enabling advanced experimentation and discovery. In May 2023, GenScript expanded the capacity of its life sciences facility in Jiangsu, China, to produce oligonucleotides and peptides. The expansion builds on the leading provider's reputation to support scientists around the globe by offering high-quality peptides and oligos for 20 years.

The pharmaceutical and biotechnology companies segment is expected to grow significantly over the forecast period. Oligonucleotides are key in modulating gene expression, targeting specific genetic sequences, and facilitating various molecular biology techniques. In September 2024, Lilly partnered with AI-driven startup Genetic Intelligence, Inc. in a USD 409 million deal to develop new drugs, specifically those targeting RNA-targeted therapies. Eli Lilly will use RNA-targeted AI platform (Genetic Leap) to develop oligonucleotide drugs for selected targets.

Regional Insights

The North America oligonucleotide synthesis market dominated the oligonucleotide synthesis industry with the largest revenue share of 31.9% in 2024. The large share is mainly attributable to the local presence of many companies and research institutes, creating high demand for oligonucleotides. Major pharmaceutical and biotechnology companies also drive the demand for the market. Canada focuses on personalized medicine and innovative therapeutic approaches, and its strong healthcare system and investments in life sciences contribute to the need for oligonucleotides in both therapeutic and diagnostic applications.

U.S. Oligonucleotide Synthesis Market Trends

The U.S. oligonucleotide synthesis market dominated the North American market, accounting for the largest revenue share in 2024. This market demand can be attributed to the country’s robust healthcare infrastructure, significant research and development investments, and a thriving pharmaceutical and biotechnology industry. Furthermore, as of April 2024, the New Drug Application (NDA) of the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) approved 19 oligonucleotide therapies for rare genetic diseases.

Europe Oligonucleotide Synthesis Market Trends

The Europe oligonucleotide synthesis market held a substantial market share in 2024. The European Union's funding programs and collaborative research initiatives contribute to the market's growth. In May 2025, in response to U.S. research funding cuts, Europe launched a USD 566 million initiative to attract top scientists from the U.S. The plan is expected to strengthen the European Research Council and offer “super grants” to top researchers.

Asia Pacific Oligonucleotide Synthesis Market Trends

The Asia Pacific oligonucleotide synthesis market is expected to grow at the fastest CAGR of 14.9% over the forecast period, driven by key players' growing interest in gaining higher profits in emerging markets. Players adopt strategies such as acquisitions, collaborations, and distribution agreements to achieve a higher market share and increase their revenue generation. Furthermore, Japan, China, and India, among other countries, are witnessing several initiatives in the oligonucleotide synthesis market, thereby driving the regional market. For instance, in September 2023, Insud Pharma inaugurated its first Oligonucleotides Centre in Hyderabad (India) at Chemo India Formulation, its wholly-owned subsidiary.

The China oligonucleotide synthesis market led the regional market, accounting for the largest revenue share in 2024. This growth is primarily fueled by increased investments in biotechnology, rising research & development initiatives, and a growing demand for targeted therapies and diagnostics.

Key Oligonucleotide Synthesis Company Insights

Some major companies in the oligonucleotide synthesis industry are Thermo Fisher Scientific Inc., Merck KGaA, Danaher, and Revvity Discovery Limited. These companies stay competitive by investing in advanced technologies, expanding research capabilities, forming strategic partnerships, and scaling production to meet the growing demand for RNA-based therapies, genomics, and personalized medicine worldwide.

• Thermo Fisher Scientific Inc. offers laboratory products and services, specializing in oligonucleotide synthesis. The company offers advanced synthesis technologies for research, diagnostics, and therapeutic applications, supporting innovations in genomics, gene editing, and RNA-based therapies and enabling the development of personalized medicine.

• Merck KGaA is a science and technology company specializing in oligonucleotide synthesis for genomics, gene editing, and RNA-based therapies. Its offerings include high-quality reagents and services, supporting advancements in molecular biology research, diagnostics, and the development of targeted treatments.

Recent Developments

• In February 2025, the Jawaharlal Nehru India Centre for Advanced Scientific Research held the first Nucleic Acid Therapeutics Regional Meeting. The meeting fostered industry-based and academic research for the development of oligonucleotide therapeutics.

• In January 2025, Maravai LifeSciences acquired relevant assets and intellectual property from Molecular Assemblies (MAI). Fully Enzymatic Synthesis technology (Molecular Assemblies' proprietary) is expected to enhance oligonucleotide and mRNA manufacturing capabilities within TriLink BioTechnologies.

• In December 2024, Co-Dx and CoSara Diagnostics Pvt. Ltd opened an oligonucleotide synthesis facility in Ranoli, India. Aligned with the “Make in India” initiative, the facility is designed to manufacture Co-Primers oligos in-house

Oligonucleotide Synthesis Market Report Scope

Global Oligonucleotide Synthesis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global oligonucleotide synthesis market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million; 2018 - 2030)

  • Oligonucleotides

    • Product Type

      • Column-based Oligos

      • Array-based Oligos

    • Nucleic Acid Type

      • DNA

      • RNA

  • Equipment/Synthesizer

  • Reagents

  • Services

    • Oligo Synthesis

      • 25 nmol

      • 50 nmol

      • 200 nmol

      • 1000nmol

      • 10,000 nmol

    • Purification

    • Modification

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • PCR Primers

  • PCR Assays and Panels

  • Sequencing

  • DNA Microarrays

  • Fluorescence In Situ Hybridization (FISH)

  • Antisense Oligonucleotides

  • Other Applications

• End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Academic Research Institutes

  • Diagnostic Laboratories

  • Pharmaceutical and Biotechnology Companies

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait